European Commission approves Enspryng for neuromyelitis optica spectrum disorder
The European Commission has approved Enspryng for treatment of adults and adolescents with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, according to a Roche press release.
Enspryng (satralizumab), a subcutaneous injection administered every 4 weeks, may be used as monotherapy or in combination with immunosuppressive therapy in people aged 12 years and older, with home-dosing being an option after appropriate training, the release said.
“Building on our growing scientific understanding of neuroimmunological conditions, we are confident Enspryng can transform how people with NMOSD are treated by fitting into their day-to-day lives.” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Roche, said in the release.
The approval is supported by results of two phase 3 studies that showed the therapy’s sustained efficacy, the release said.
Read more about